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Background: Malnutrition, inflammation, and atherosclerosis (MIA) syndrome is associated with a high mortality rate
in patients with end-stage renal disease. However, the clinical relevance of MIA syndrome in kidney transplantation (KT)
recipients remains unknown.
Methods: We enrolled 1348 adult KT recipients. Recipients were assessed based on serum albumin, cholesterol, or
body mass index for the malnutrition factor and C-reactive protein level for the inflammation factor. Any history of
cardiovascular (CV), cerebrovascular, or peripheral vascular disease satisfied the atherosclerosis factor. Each MIA factors
were assessed by univariate analysis and we calculated an overall risk score by summing up scores for each independent
variable. The enrolled patients were divided into 4 groups depending on the MIA score (0, 2–4, 6, 8–10).
Results: The patients with higher MIA score showed worse outcome of fatal/non-fatal acute coronary syndrome
(ACS) (p < 0.001) and composite outcomes of ACS and all-cause mortality (p < 0.001) than with the lower MIA
score. In multivariate analysis, ACS showed significantly higher incidence in the MIA score 8-10 group than in the
MIA score 0 group (Hazard ratio 6.12 95 % Confidence interval 1.84–20.32 p = 0.003).
Conclusions: The presence of MIA factors before KT is an independent predictor of post-transplant CV outcomes.
Keywords: Acute Coronary Syndrome, Atherosclerosis, Cardiovascular Outcome, Inflammation, Kidney
Transplantation, MalnutritionBackground
Cardiovascular disease (CVD) is the main cause of morbid-
ity and mortality in patients with end-stage renal disease
(ESRD) despite major research efforts and improvements
in dialysis technology [1]. There have been many discus-
sions about traditional risk factors that may not sufficiently
predict CVD occurrence in patients with ESRD [2–5].
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ESRD [6]. The 3 factors of MIA syndrome interact with
each other and create a vicious cycle [7]. Malnutrition or
protein-energy wasting may aggravate existing inflam-
mation, accelerating atherosclerosis and increasing
susceptibility to infection [8, 9]. Chronic inflammation is
common in patients with chronic kidney disease, in part
because of the decreased glomerular filtration rate
(GFR), and also because of the dialysis procedure [10,
11]. Inflammation plays a key role in atherosclerosis and
may contribute to an increased cardiovascular mortality
associated with endothelial dysfunction and increased
oxidative stress [9, 12]. With these observations, the
term malnutrition inflammation complex syndrome
(MICS) was coined.rticle distributed under the terms of the Creative Commons Attribution License
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for patients with ESRD. With the development and ad-
vancement of immunosuppressive agents, renal allograft
survival rates have improved over the years. Even after
the transplantation, CVD is an important cause of death
[13]. Moreover, the immunosuppressive agents increase
atherosclerotic risk by elevating blood pressure and by
aggravating several metabolic profiles such as dyslipid-
emia and new onset diabetes after transplantation
(NODAT) [13, 14].
While several studies about MICS or MIA syndrome
in patients with ESRD have been reported [6, 7, 9, 15],
only a few reports have evaluated transplant wait-listed
patients with ESRD and the association between pre-
transplant parameters (e.g., C-reactive protein (CRP), al-
bumin) and post-transplant outcomes [16–18]. Thus,
the clinical relevance of MIA syndrome in kidney trans-
plant recipients remains unclear. We hypothesized that




This study was approved by the institutional review
board at Seoul National University Hospital (H-1302-
018-462), and the need for informed consent from the
patients was waived because of the retrospective study
design. All clinical investigations were conducted in
accordance with the guidelines of the 2008 Declaration
of Helsinki.
Study design and patients
This study was performed as a retrospective, multicenter
study. Among the patients in whom kidney transplant-
ation had been performed at Seoul National University
Hospital, Seoul National University Boramae Medical
Center, Seoul National University Bundang Hospital, and
Asan Medical Center from Jun. 1999 through Dec. 2011,
we reviewed the medical records of 2425 individuals and
collected data from 1348 patients. All patients were
adults (age ≥ 15 years); had pretransplant CRP, serum
albumin, and cholesterol data available; received renal
transplants; and were followed for more than one year
after transplantation (Fig. 1). Patients with a previous
transplantation history and those with unavailable
pretransplant laboratory profiles were excluded. Patients
with a follow-up duration less than one year were also
excluded from the analysis.
Clinical parameters such as age at the time of kidney
transplantation, sex, body mass index (BMI), laboratory
test results (CRP, serum albumin, cholesterol, intact
patathyroid hormone (PTH), and cytomegalovirus (CMV)
immunoglobulin G (IgG) status), underlying diseases
(hypertension, diabetes mellitus (DM), ischemic heartdisease, liver cirrhosis, and tuberculosis), dialysis modality,
and duration of dialysis before transplantation were col-
lected. Donor factors such as age at transplantation, sex,
donor source, and CMV IgG status were evaluated.
Definitions and grouping
We evaluated enrolled patients by defining and calculat-
ing MIA factors. Between patients with or without acute
coronary syndrome (ACS), the univariate Cox regression
was performed to identify the influence of variables such
as serum albumin, cholesterol, and BMI for malnutrition
factor, and CRP for inflammation factor. Researchers
considered the atherosclerosis factor to be satisfied if
there was any history of CV, cerebrovascular, or periph-
eral vascular disease. Recipients were assessed according
to the quartile value of pretransplant albumin and CRP.
We evaluated each independent variable for the assump-
tion of proportional hazards. From the regression model,
the β-coefficient of each variable was assigned score by
rounding to the nearest integer [19]. After that, we cal-
culated an overall risk score by summing up the scores
for each independent predictor variable for a given pa-
tient. Subsequently, the enrolled patients were divided
into four groups depending on the MIA score consider-
ing score homogeneity (0, 2–4, 6, 8–10).
Researchers have checked cholesterol, albumin, and
CRP levels at least two time points within one year be-
fore transplantation and used mean value of the each
variables. The minimum interval between the two time
points was four weeks.
The cardiovascular outcome of fatal/non-fatal ACS was
defined as usual ACS, which includes unstable angina/
non-ST elevated myocardial infarction (MI) and ST ele-
vated MI. In this study all the patients with ACS were
confirmed by coronary angiography.
Primary and secondary objectives
The primary objective of the study was to evaluate
whether pretransplant MIA factors affect the occurrence
of fatal/non-fatal ACS after transplantation. The second-
ary objective of the study was to evaluate the composite
of ACS with all-cause mortality and graft failure. Graft
failure was defined as a requirement for maintenance
dialysis or re-transplantation.
Statistical analysis
All analyses and calculations were performed by using the
IBM SPSS Statistics V21.0 (IBM Corporation, Armonk,
NY, USA). Continuous variables were expressed as the
mean ± standard deviation and as the percentage for cat-
egorical variables. Continuous and categorical data were
compared by using the Student’s t-test and the chi-square
test, respectively. The ACS-free survival rates and other
event-free survival rates were calculated by using the
Fig. 1 Defining the study population. We reviewed the medical records of 2425 individuals and collected data from 1348 patients
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was performed by using the log-rank test. The Cox regres-
sion model was used to identify risk factors and to calcu-
late the hazard ratio (HR) and 95 % confidence interval
(CI). The corresponding β-coefficient for each independ-
ent variable from the regression model for the occurrence
of ACS was used to calculate MIA score. Differences with
p < 0.05 were considered statistically significant.
Results
Baseline characteristics of enrolled patients
The baseline characteristics of the 1348 enrolled patients
are described in Table 1. The mean age of patients at
transplantation was 43.0 years, and 57.2 % were men
(n = 771). The mean follow-up duration was 57.0 ±
36.0 months. The pretransplant BMI, albumin, CRP, and
cholesterol levels were 22.4 ± 3.2 kg/m2, 3.7 ± 0.5 g/dL,
0.48 ± 1.17 mg/dL, and 158.8 ± 40.9 mg/dL, respectively.
Hypertension was diagnosed in 1198 patients (88.9 %)
and DM was diagnosed in 275 patients (20.4 %). One-
hundred fifteen patients (8.5 %) had experienced at least
one of the following vascular diseases: CVD, cerebrovas-
cular disease, or peripheral vascular disease. There were
more patients with dyslipidemia in the higher MIA score
group (63.8 % in MIA score 8-10 group, 26.6 % in aver-
age). There was no significant difference in total choles-
terol level between the patients who took the lipid
lowering agent and the patients who did not (156.9 ±
45.8 vs. 159.4 ± 38.8, p = 0.38, data not shown). Preemptive
kidney transplantation was performed in 217 patients
(16.1 %), and hemodialysis was performed frequently be-
fore transplantation (n = 679, 60.0 % of dialysis patients).
Most enrolled patients received only kidney transplant-
ation (n = 1211, 89.8 %), and most grafts were received
from living donors (n = 1065, 79.0 %). The prescription ofimmunosuppressive agents after transplant was not differ-
ent between the groups.
Pretransplant MIA factor profile
The HR for cardiovascular disease of albumin, CRP, and
previous history of vascular disease was 2.040, 1.893,
and 6.41 respectively. The corresponding scores for the
same MIA factors were 2, 2, and 6 (Table 2). Seven-
hundred thirty-one patients (54.2 %) did not satisfy any
of the MIA factors (MIA score 0). Three-hundred
ninety-eight patients (29.5 %) had one MIA factor with
score 2 and 67 patients (5.0 %) had 1 MIA factor with
score 6. Nine patients had all of three MIA factors (score
10). Other MIA score groups and each component are
shown in Table 3. The distribution of MIA scores of the
patients with pre-emptive transplantation was not differ-
ent with the patients who underwent dialysis before
transplantation (p = 0.451, data not shown).
Factors related to the occurrence of ACS
Univariate analysis of the association between ACS and
covariates showed a significant relationship with age
(HR, 1.08; 95 % CI, 1.03–1.12; p = 0.001); male sex (HR,
3.54; 95 % CI, 1.45–8.60; p = 0.005); BMI (HR, 1.11;
95 % CI, 1.00–1.23; p = 0.049); DM (HR, 3.55; 95 % CI,
1.78–7.05; p < 0.001); deceased donor (HR, 2.72; 95 %
CI, 1.12–6.61; p = 0.027); NODAT (HR, 2.80; 95 % CI,
1.24–6.32; p = 0.013); previous history of vascular disease
(HR, 6.41; 95 % CI, 3.09–13.33; p < 0.001); and the MIA
score group (10 vs. 0; HR, 32.96; 95 % CI, 7.30–148.94;
p < 0.001 and 8–10 vs. 0; HR, 11.18; 95 % CI, 4.12–
30.33; p < 0.001). Of these, MIA score 8–10 (HR, 6.12;
95 % CI, 1.84–20.32; p = 0.003); age (HR, 1.05; 95 % CI,
1.01–1.10; p = 0.008); NODAT (HR, 2.88; 95 % CI, 1.03–
8.10; p = 0.045); albumin (HR, 2.33; 95 % CI, 1.11–4.88;
Table 1 Baseline characteristics of the study subjects
MIA score 0 MIA score 2–4 MIA score 6 MIA score 8–10 Total p-value
(n = 731) (n = 502) (n = 67) (n = 48) (N = 1348)
Age at the transplantationa 41.1 ± 11.9 42.8 ± 12.0 52.5 ± 10.4 57.7 ± 8.0 43.0 ± 12.3 <0.001‡
Recipient’s sex (male, %) 54.7 57.4 67.2 79.2 57.2 0.003
Body weight (kg)a 59.9 ± 10.7 61.4 ± 12.0 62.4 ± 11.0 64.8 ± 9.0 60.8 ± 11.2 0.003‡
Height (cm)a 164.2 ± 8.6 164.4 ± 8.8 164.4 ± 7.8 166.4 ± 7.4 164.4 ± 8.6 0.374
BMI (kg/m2)a 22.1 ± 2.9 22.6 ± 3.5 23.0 ± 3.3 23.3 ± 2.6 22.4 ± 3.2 0.001§
Current smoker (%) 10.6 9.1 23.3 6.4 9.8 <0.001
Past medical history
Hypertension (%) 88.5 87.3 100.0 95.8 88.9 0.007
DM (%) 14.1 21.5 49.3 64.6 20.4 <0.001
Vascular diseases (%)b 0.0 0.0 100.0 100.0 8.5 <0.001
Dyslipidemia (%) 21.4 29.1 35.0 63.8 26.6 <0.001
Renal disease causing ESRD 0.033
DM (%) 17.4 19.4 14.3 12.2 17.8
Hypertension (%) 10.0 9.7 17.9 12.2 10.4
Glomerulonephritis (%) 30.5 28.4 21.4 22.0 29.0
PKD (%) 5.3 3.9 14.3 4.9 5.2
Others (%) 36.8 38.6 32.1 48.7 37.6
Laboratory Findings
Serum albumin (g/dl)a 3.9 ± 0.4 3.4 ± 0.5 3.9 ± 0.3 3.3 ± 0.6 3.7 ± 0.5 <0.001‡§
CRP (mg/dl)a 0.11 ± 0.11 0.97 ± 1.62 0.15 ± 0.13 1.25 ± 2.46 0.48 ± 1.17 <0.001‡§
Total cholesterol (mg/dl)a 161.6 ± 37.5 155.7 ± 44.9 156.5 ± 38.4 151.6 ± 48.5 158.8 ± 40.9 0.044
Triglyceride (mg/dl)a 120.8 ± 67.2 125.9 ± 99.2 135.6 ± 89.5 133.6 ± 72.9 123.9 ± 81.1 0.419
LDL cholesterol (mg/dl)a 91.5 ± 32.1 91.3 ± 31.8 87.2 ± 31.6 93.6 ± 43.2 91.3 ± 32.4 0.772
Intact PTH (pg/ml)a 262.2 ± 312.8 238.7 ± 242.7 181.8 ± 183.8 249.7 ± 273.3 249.6 ± 279.4 0.29
CMV IgG positive (%) 93.1 96.0 92.9 96.3 94.8 0.475
Dialysis before TPL (%) 82.2 85.7 88.1 85.4 83.9 0.491
Preemptive TPL (%) 17.8 14.3 11.9 14.6 16.1 0.491
HD:PD:both or switch (%) 60.7:18.4:3.1 57.8:24.0:3.9 63.3:18.3:6.5 68.8:14.6:2.0 60.0:20.4:3.5 0.308
Dialysis duration (months)a 26.7 ± 38.8 27.7 ± 38.0 38.4 ± 50.8 21.2 ± 27.7 27.4 ± 38.8 0.098
Donor information
Deceased donor (%) 20.1 21.3 29.9 17.0 21.0 0.003














Table 1 Baseline characteristics of the study subjects (Continued)
Donor’s sex (male, %) 52.5 57.7 50.0 62.5 54.6 0.178
CMV IgG positive (%) 54.9 69.9 47.8 60.4 60.3 <0.001§
TPL (KT only : SPK : Others, %) 89.1:3.1:7.8 91.4:4.8:3.8 85.1:4.5:10.4 89.6:2.1:8.3 89.8:3.8:6.4 0.053
Immunosuppressive agents
Steroid maintenance strategy (%) 92.6 89.5 100 85.7 90.9 0.625
CNI (CsA : Tacrolimus, %) 34.2:65.3 35.8:63.6 22.8:75.4 29.7:70.3 34.0:65.4 0.254
Antimetabolites (Aza : MMF, %) 6.5:88.1 10.2:79.4 10.5:80.7 8.6:82.9 8.0:84.6 0.095
BMI body mass index, DM diabetes mellitus, ESRD end-stage renal disease, PKD polycystic kidney disease, CRP c-reactive protein, LDL low-density lipoprotein, TPL transplantation, HD hemodialysis, PD peritoneal dialysis,
KT kidney transplantation, SPK simultaneous pancreas-kidney transplant, CNI calcineurin inhibitor, CsA cyclosporine A, Aza azathioprine, MMF mycophenolate mofetil
adata are expressed as the mean ± SD
bVascular disease included cardiovascular, cerebrovascular, and peripheral vessel diseases
‡p < 0.05 at post-hoc analysis between MIA score 0 group and MIA score 8–10 group














Table 2 Factors associated with the occurrence of ACS
Univariate Multivariatea
HR 95 % CI p-value HR 95 % CI p-value
Age 1.08 1.03–1.12 0.001 1.05 1.01–1.10 0.008
Male 3.54 1.45–8.60 0.005 2.26 0.89–5.71 0.085
Smoking 1.92 0.77–4.78 0.162
BMI (continuous variable) 1.11 1.00–1.23 0.049
Hypertension 4.27 0.58–31.44 0.154 - - -
DM 3.55 1.78–7.05 <0.001 2.58 0.99–6.76 0.054
Dialysis before KT (vs. preemptive) 1.58 0.46–5.38 0.469 - - -
Dialysis vintage (months) 1.01 0.99–1.013 0.146
Cholesterol (<150 mg/dL) 1.46 0.69–3.07 0.324
Intact PTH 1.00 0.99–1.00 0.384
Recipient CMV IgG (+) 0.01 0.01–20.16 0.998
Donor sex (male) 0.64 0.31–1.29 0.208 - - -
Donor age 1.03 0.99–1.06 0.094 - - -
Deceased donor (vs. living donor) 2.72 1.12–6.61 0.027 2.17 0.80–5.91 0.128
Donor CMV IgG (+) 0.891 0.44–1.79 0.745
CsA (vs. tacrolimus) 1.9 0.91–3.95 0.085 - - -
NODAT 2.80 1.24–6.32 0.013 2.88 1.03–8.10 0.045
CMV disease 0.046 0.01–14.33 0.686 0.15 0.01–41.48 0.712
MIA factors
Albumin (lowest quartile vs. others) 2.04 0.98–4.24 0.056 2.33 1.11–4.88 0.026
CRP (highest quartile vs. others) 1.89 0.94–3.82 0.075 1.55 0.75–3.20 0.237
Previous history of vascular diseasea 6.41 3.09–13.33 <0.001 2.61 1.08–6.27 0.033
MIA scorea
0 Reference Reference
2 1.17 0.45–3.05 0.742 2.14 0.77–5.96 0.147
4 2.51 0.79–8.03 0.121 1.86 0.39–8.73 0.436
6 5.23 1.76–15.53 0.003 2.93 0.90–9.54 0.075
8 7.53 2.28–24.85 0.001 3.11 0.73–13.29 0.125
10 32.96 7.30–148.94 <0.001 34.29 8.29–141.84 <0.001
Group by MIA scorea
0 Reference Reference
2–4 1.33 0.56–3.16 0.517 2.05 0.79–5.35 0.142
6 5.28 1.78–15.68 0.003 3.06 0.94–9.99 0.063
8–10 11.18 4.12–30.33 <0.001 6.12 1.84–20.32 0.003
Data were analyzed by using the Cox regression, Backward LR method in the multivariate analysis
ACS acute coronary syndrome, DM diabetes mellitus, KT kidney transplantation, NODAT new onset diabetes after transplantation, CsA cyclosporine A, Alb albumin
aWe performed multivariate analysis about “MIA score”, “Previous history of vascular disease”, and “Group by MIA score” separately with other variables
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2.61; 95 % CI, 1.08–6.27; p = 0.033) remained significant
predictors on multivariate analysis (Table 2). There was
no association between ACS and smoking history, hyper-
tension, cholesterol level, intact PTH level, recipient and
donor CMV IgG antibody status, donor sex, donor age,
dialysis modality before transplantation, immunosup-
pressive agents, or CMV disease.ACS based on each MIA factor and impact of ACS on
mortality
There was a significant difference in occurrence of ACS
(p = 0.042) and composite outcomes (p = 0.016) between
the lowest quartile and the others when albumin level
was analyzed (Fig. 2a, b). Our findings indicate that in-
creased CRP level was not predictive of ACS (p = 0.106)
or composite outcomes (p = 0.187) (Fig. 2c, d). Previous
Table 3 Crosstable by MIA score group and each component
MIA score 0 MIA score 2 MIA score 4 MIA score 6 MIA score 8 MIA score 10 Total
(n = 731) (n = 398) (n = 104) (n = 67) (n = 39) (n = 9) (N = 1348)
Albumin lower quartile (%)a 0 191 (48.0) 104 (100) 0 24 (61.5) 9 (100) 335 (24.3)
CRP upper quartile (%)a 0 207 (52.0) 104 (100) 0 15 (38.5) 9 (100) 340 (24.9)
Atherosclerosis (%)a 0 0 0 67 (100) 39 (100) 9 (100) 116 (8.5)
aData are expressed as patients number (% by MIA score group).
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vascular, or peripheral vascular disease) was significantly
related with ACS (p < 0.001) and composite outcomes
(p < 0.001) (Fig. 2e, F). In 1233 patients without a history
of vascular disease, 21 patients experienced ACS after
transplantation. However, in 115 patients with a history
of vascular disease, 12 patients experienced ACS.
The all-cause mortality was significantly higher in the
patients with post-transplant CV events than in the
other patients (21.2 % vs. 2.5 %; p < 0.001). Cardio-
vascular events were the second most common cause of
post-transplant mortality in this study population.
MIA score groups and occurrence of ACS
The patients were divided into 4 groups depending on
MIA scores and the ACS, graft outcome, and mortality
were evaluated between groups. The ACS occurred in
total of 33 patients (2.4 %). The patients with higher MIA
scores showed worse ACS outcomes (p < 0.001, Fig. 3a)
and composite outcomes of ACS and death (p < 0.001,
Fig. 3b) than those in the group with lower MIA scores.
To eliminate the strong effect of vascular disease
history, we divided the patients by history of vascular
disease and evaluated separately. In patients without
previous vascular disease, ACS and composite outcome
did not show significant difference according to the
quartile value of albumin and CRP (Fig. 4a, c). However,
in the patients with a history of vascular disease, ACS
(p = 0.002, Fig. 4b) and composite outcome (p = 0.011,
Fig. 4d) occurred more in the lowest albumin + highest
CRP quartile group than in the other groups.
Other outcomes based on MIA factor
The overall survival rate was 97.0 %, and all-cause mor-
tality rate between the groups did not differ based on
MIA score. Infection (23 patients, 56.1 %) and cardiovas-
cular disease (5 patients, 12.2 %) were the most common
causes of death after transplantation. Eight patients
(19.5 %) died suddenly from unknown cause.
During a mean follow-up duration of 57.0 ± 36.0 months,
the overall graft survival rate was 94.6 %, excluding pa-
tients who died with functioning grafts. Graft outcome
and all-cause mortality were not different between the
groups (p = 0.973 and p = 0.183) (Fig. 3c, d). Acute rejec-
tion and acute kidney injury related with sepsis was thefirst and the second most common cause of graft failure
(23.3 % and 13.7 %, respectively). Transplant glomerulopa-
thy (9.6 %), recurred glomerulonephritis (6.8 %), non-
compliance to immunosuppressive agents (6.8 %), BK
virus-induced nephropathy (5.5 %), and renal infarct
(4.1 %) were the next common causes. The number of
total and graft failure cases in MIA score 6 and 8-10
groups were not enough to perform statistical analysis on
the graft failure causes.
The occurrence of CMV disease after KT was not differ-
ent between the groups, which could be a strong predictor
of cardiovascular complications (7.7 %, 4.3 %, 7.1 %, and
3.7 % in MIA score 0, 2–4, 6, and 8–10; p = 0.359).
Discussion
In this study of 1348 kidney transplant recipients, we re-
port independent associations of pretransplant MIA
score with the occurrence of post-transplant ACS. To
date, few reports have examined the association between
pretransplant MICS and post-transplant outcomes. Most
of these reports focused on different outcomes such as
mortality (including cardiovascular mortality and all-
cause mortality), delayed graft function, chronic allograft
nephropathy, or graft outcomes [17, 20–23]. Some were
either small in sample size [18] or focused on association
only with one MIA factor (albumin or CRP level) [24].
To our knowledge, this is the first multicenter study on
the occurrence of ACS in kidney transplant recipients
with combined factor for considering pretransplant
MIA score.
We defined malnutrition and inflammation arbitrarily in
some ways. However, an albumin level < 3.5 mg/dL was
not only a lower quartile value, but also “below normal
level”. Also a cholesterol level < 150 mg/dL originated with
the malnutrition standards of dialysis patients [25]. In
2003, the American Heart Association and the Centers for
Disease Control and Prevention endorsed cutoff points
of < 1 mg/dL for low-risk CRP in the adult non-
transplanted population, but we applied the lower cutoff
point (>0.5 mg/dL) for CRP as we used higher quartile of
enrolled populations [26].
Interest in CV outcomes after kidney transplantation
is likely to increase because long-term graft outcomes
have improved. The current study revealed that ACS
were significantly high in the higher MIA score group
Fig. 2 (See legend on next page.)
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Fig. 2 Kaplan-Meier curves of fatal/non-fatal acute coronary syndrome (ACS) and composite outcomes of ACS and death in patients with different
MIA factors. a-b. The patients in the lowest albumin quartile showed worse ACS outcomes (p = 0.042) and composite outcomes of ACS and death
(p = 0.016) than the others. c-d. The patients in the highest CRP quartile showed tendency of worse ACS outcomes (p = 0.106) and composite
outcomes of ACS and death (p = 0.187) although statistically insignificant. e-f. The patients with previous history of vascular disease showed poor
outcome of ACS (p < 0.001) and composite outcomes of ACS and death (p < 0.001) than the others
Hwang et al. BMC Nephrology  (2015) 16:109 Page 9 of 12compared to the lower MIA score group after multivariate
analysis by adjusting possible factors with association. In-
creasing patient age, DM, male sex, hypertension, dyslipid-
emia, and cigarette smoking are well known risk factors
for CV disease in general [27]. Non-traditional risk factors
such as dialysis vintage before transplantation, rejection,Fig. 3 Kaplan-Meier curves of ACS, composite outcomes of ACS, graft outc
higher MIA score showed worse outcome of ACS (p < 0.001) and composit
scores. c-d. Graft outcome and all-cause mortality were not different betweanemia, proteinuria, reduced kidney function following
transplantation, and elevated inflammatory markers have
been associated with increased CV risk in various studies
[28, 29]. Pretransplant CV disease is the most important
predictor of post-transplant CV events [30]. Further, both
pretransplant diabetes and NODAT are associated withome, and death in patients in MIA score groups. a-b. The patients with
e outcomes of ACS and death (p < 0.001) than those with lower MIA
en the groups (p = 0.973 and p = 0.183, respectively)
Fig. 4 Kaplan-Meier curves of ACS and composite outcomes of ACS and death in divided patients by previous history of vascular disease. a-c. In the
patients without a history of vascular disease, ACS (p = 0.567) and composite outcome (p = 0.673) did not show significant difference according to the
quartile value of albumin and CRP. b-d. In the patients with a history of vascular disease, ACS (p = 0.002) and composite outcome (p = 0.011) occurred
more frequently in the patients in the lowest albumin + highest CRP quartile group than in the other patients
Hwang et al. BMC Nephrology  (2015) 16:109 Page 10 of 12the occurrence of post-transplant CV outcomes [31]. Our
results are meaningful because we showed the independ-
ent association between the pretransplant MIA score
group with ACS after all known risk factors were adjusted.
Our data showed significant result only in ACS and
composite outcome. Graft function and other risk
factors are known to be associated with cardiovascular
outcome [32]. However, in this study, graft failure did
not affect the occurrence of fatal/non-fatal ACS.
In this study, pretransplant CRP level did not show in-
dependent association with post-transplant ACS, althoughseveral former studies reported an association between
high CRP levels and CV outcomes [18, 24, 29]. The occur-
rence of ACS in the patients with sustained high CRP
levels after transplantation cannot be verified, because
post-transplant one-year CRP value was not measured
routinely in all patients.
The overall mortality rate was only 3.0 % in this study.
The population was too small to analyze statistical sig-
nificance and to affect the composite outcome with
ACS. For the other aspect, patients with a history of
vascular disease are usually selected more carefully
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another reason why the mortality rate was not different
with others. Graft failure also failed to show a difference
between groups.
The nutritional status of Korean might be different
with a Western population and the risk of coronary
heart disease is lower in Korean population [33]. The
CVD is not the primary cause of death even though the
mortality of unknown cause (19.5 %) was assumed as
CV death. To the best of our knowledge, our study is
notable for enrolling the largest number of Korean pa-
tients in multicenter to provide the analysis for the
correlation between the pretransplant MIA factors and
ACS. Enrolled clinical institutions are active centers for
transplantation in South Korea. We evaluated patients
with relatively simple standards that can be easily ap-
plied. Also, we used cardiovascular outcome as “ACS”,
which is specific outcome of ischemic heart disease. The
term ‘major adverse cardiac event’ was commonly used
for several studies, but it is considered as inconsistent
and of heterogeneous definition [34].
The following limitations should be considered when
interpreting our results. Like all other retrospective stud-
ies, this study cannot prove a causal relationship. There
could be inevitable biases which are patient selection,
follow-up, or interpretation of the outcomes. However,
we tried to minimize the possible biases by considerate
medical record review and by including every factor
which can possibly affect the outcome of patients. Also,
it was not able to perform the true assessment of nutri-
tion such as subjective global assessment of nutritional
status. The method used to calculate the MIA score
might need further validation even which was published
previously in other fields [19]. The CRP was not a
routine laboratory test before and after transplantation
in many clinical institutions, and patients who did not
have pretransplant serum CRP levels measured were ex-
cluded from analysis. Moreover, transferrin is a known
marker of malnutrition in patients with ESRD [35], but
we could not evaluate transferrin as a malnutrition
marker. As the population of this study is all Asian, the
results are not directly comparable with US or European
cohorts. The heterogeneity of the populations (trans-
plantation types and preemptive KT vs. dialysis before
KT) can be the other limitation of this study although
we verified such clinical findings were not different
between the MIA score groups. Lastly, we applied our
own standard for classification because there is no
standard method to assess malnutrition and inflamma-
tion in patients with ESRD.
Conclusions
We have shown that the presence of higher MIA score
before kidney transplantation is an independent predictorof post-transplant ACS. Further investigations are needed
to assess whether improving MIA syndrome would impact
the occurrence of ACS after kidney transplantation and
whether active evaluation and treatment for coronary
artery disease would be helpful for improving outcome in
patients with high MIA score.
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